DESCOVY FOR PrEP™ Candidates

INDICATION

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

A routine visit could be your opportunity to recognize a patient at risk1

Identifying candidates for DESCOVY FOR PrEP

HIV risk factors can be behavioral, biological, or epidemiologic, and may include

Past or current STIs

Sexual activity in a high-prevalence area or social network

Condomless sex

Self-identified HIV risk

Sexual partners of unknown HIV-1 viremic status

When prescribing DESCOVY FOR PrEP, consider the following1:

DESCOVY FOR PrEP should be prescribed only to individuals who are confirmed to be HIV-1 negative immediately prior to initial use and who do not have signs or symptoms consistent with acute HIV infection.

While using DESCOVY FOR PrEP, HIV-1 screening tests should be repeated at least every 3 months, and upon diagnosis of any STIs.

Individuals must strictly adhere to the dosing schedule because the effectiveness of DESCOVY FOR PrEP is strongly correlated with adherence.

Use DESCOVY for HIV-1 PrEP to reduce the risk of HIV as part of a comprehensive prevention strategy to reduce the risk of STIs.6

When you see STIs in patients at risk, talk to them about DESCOVY FOR PrEP right away.

MSM=men who have sex with men; STI=sexually transmitted infection.